7 hours Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now Zacks

   X     

16 hours Zacks Earnings Trends Highlights: Netflix and Johnson & Johnson Zacks

   X     

1 day 3-Stock Lunch: Netflix, Johnson & Johnson, Travelers YouTube

   X     

1 day Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings Fast Company

   X     

1 day Johnson & Johnson Dips On Q4 Earnings: Here’s What The Market Isn’t Seeing Seeking Alpha

   X     

1 day Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript Seeking Alpha

   X     

1 day Downside risk from talc lawsuit, Stelara generic competition is ‘manageable’: JNJ CFO Joe Wolk Yahoo Finance

   X     

1 day J&J’s Depression Drug Spravato Gets FDA Nod for Monotherapy Use Zacks

   X     

1 day J&J’s Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance Zacks

   X     

1 day Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings Yahoo Finance

   X     

1 day Pre-Markets Keep Optimistic, Earnings Beats for JNJ, PG, ALLY & More Zacks

   X     

1 day J&J Skids After Dow Giant Beat Earnings Views, But ‘Prudent’ Guidance Disappoints Investor's Business Daily

   X     

1 day Johnson & Johnson 2024 Q4 – Results – Earnings Call Presentation Seeking Alpha

   X     

1 day Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics Zacks

   X     

1 day Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth Yahoo Finance

   X     

1 day Netflix, Oracle, Travelers and Procter & Gamble rise premarket; J&J falls Investing.com

   X     

1 day J&J CFO Joe Wolk: Anticipating 3% operational growth in 2025 despite ‘significant’ headwinds YouTube

   X     

1 day Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates Zacks

   X     

1 day Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance MarketWatch

   X     

1 day J&J beats quarterly sales and profit estimates on cancer drug sales Investing.com

   X     

1 day J&J tops earnings estimates amid strong demand for cancer treatments Investing.com

   X     

2 days J&J Reports Strong Revenue and Profit but Faces Challenges in 2025 Yahoo Finance

   X     

2 days J&J beats quarterly sales and profit estimates on cancer drug sales Yahoo Finance

   X     

2 days These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More Yahoo Finance

   X     

2 days Q4 Earnings: 3 Consumer Staples Titans on Deck Zacks

   X     

2 days Kinder Morgan, P&G, J&J, and more set to report earnings Wednesday Investing.com

   X     

2 days Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study Zacks

   X     

3 days Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings? Zacks

   X     

3 days What Analysts Think of Johnson & Johnson Stock Ahead of Earnings Yahoo Finance

   X     

5 days Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week Seeking Alpha

   X     

6 days Pharma Stock Roundup: J&J’s ITCI Buyout, LLY’s Weak Q4 Sales Zacks

   X     

1 week Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know Zacks

   X     

1 week Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves Seeking Alpha

   X     

1 week J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug Zacks

   X     

1 week The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular Zacks

   X     

1 week JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference Zacks

   X     

1 week Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) Seeking Alpha

   X     

1 week Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal The Wall Street Journal

   X     

1 week Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal Yahoo Finance

   X     

1 week What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies Seeking Alpha

   X     

1 week J&J to Acquire Intra-Cellular for About $14.6 Billion Reddit

   X     

1 week J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug Investor's Business Daily

   X     

1 week J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal Investing.com

   X     

1 week Johnson & Johnson in talks to acquire Intra-Cellular Therapies Yahoo Finance

   X     

1 week Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal Yahoo Finance

   X     

1 week Johnson & Johnson makes $15 billion bet on mental-health drugs MarketWatch

   X     

1 week J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion Investing.com

   X     

1 week Intra-Cellular shares surge amid report J&J exploring possible takeover bid Investing.com

   X     

1 week J&J to buy Intra-Cellular Therapies for $14.6 billion Yahoo Finance

   X     

1 week Johnson & Johnson in talks to acquire Intra-Cellular Therapies Investing.com

   X     

2 weeks This Stock Is Soaring Amid Johnson & Johnson Takeover Report Yahoo Finance

   X     

2 weeks J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports Investing.com

   X     

2 weeks Johnson & Johnson Could Serve As High-Yield Bond Alternative Seeking Alpha

   X     

2 weeks FDA Accepts J&J’s Filing for Autoimmune Disease Drug Nipocalimab Zacks

   X     

2 weeks Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO’s Expanded Deal Zacks

   X     

2 weeks J&J and United Health among Thursday’s market cap stock movers Investing.com

   X     

2 weeks J&J Pauses Sales of Atrial Fibrillation Device, Stock Down Zacks

   X     

2 weeks AMD, J&J lead market cap stock movers on Wednesday Investing.com

   X     

2 weeks J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product Investor's Business Daily

   X     

2 weeks Johnson & Johnson stock sinks on Varipulse concerns Investing.com

   X     

2 weeks Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer Seeking Alpha

   X     

2 weeks Johnson & Johnson stock reaches 52-week low as markets fall FXStreet

   X     

2 weeks Johnson & Johnson: A Potential Beneficiary Of A Great Rotation Seeking Alpha

   X     

2 weeks Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors Zacks

   X     

2 weeks Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson Zacks

   X     

2 weeks Johnson & Johnson: I’m Saying Yes To This Mess Seeking Alpha

   X     

3 weeks The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer Zacks

   X     

3 weeks Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report? Zacks

   X     

3 weeks Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note Zacks

   X     

3 weeks J&J Trading Near 52-Week Low: Should You Sell the Stock? Zacks

   X     

4 weeks Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal Yahoo Finance

   X     

4 weeks J&J Snack Foods: Shares Are Still Too Expensive Seeking Alpha

   X     

4 weeks Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know Zacks

   X     

1 month Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note Zacks

   X     

1 month Johnson & Johnson: Dividend Legend At A Discount Seeking Alpha

   X     

1 month FDA Gives CRL to J&J’s BLA for Subcutaneous Rybrevant in NSCLC Zacks

   X     

1 month Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors Zacks

   X     

1 month J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports Investing.com

   X     

1 month Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It Zacks

   X     

1 month Johnson & Johnson (JNJ) Stock Moves -0.25%: What You Should Know Zacks

   X     

1 month Johnson & Johnson Just Paid Investors: Here’s How Much They Received 24/7 Wall St.

   X     

2 months Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View Seeking Alpha

   X     

2 months Pharma Stock Roundup: LLY’s Zepbound Success, FDA Updates for MRK, JNJ Zacks

   X     

2 months The Zacks Analyst Blog Highlights Home Depot, Johnson & Johnson, Salesforce, Preformed Line and Cooper-Standard Zacks

   X     

2 months Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce Zacks

   X     

2 months Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade Zacks

   X     

2 months J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids Zacks

   X     

2 months J&J baby powder lawsuits stay paused amid bankruptcy trial plans Investing.com

   X     

2 months Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know Zacks

   X     

2 months How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding Seeking Alpha

   X     

2 months J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC Zacks

   X     

2 months J&J Loses Around $24B in a Month: How to Play the Stock? Zacks

   X     

2 months Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive Seeking Alpha

   X     

2 months Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know Zacks

   X     

2 months Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript) Seeking Alpha

   X     

2 months CHMP Endorses J&J’s Rybrevant-Lazcluze Combo for Use in NSCLC Zacks

   X     

2 months Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program Yahoo Finance

   X     

2 months Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report? Zacks

   X     

2 months Compared to Estimates, J&J Snack Foods (JJSF) Q4 Earnings: A Look at Key Metrics Zacks

   X     

3 months Johnson & Johnson (NYSE:JNJ) Stock Price Down 0.2% – Time to Sell? MarketBeat

   X